Immunology and Bi...
Follow
Find
6.8K views | +0 today
 
Scooped by Gilbert Faure au nom de l'ASSIM
onto Immunology and Biotherapies
Scoop.it!

Rheuminations: Infection or RA Flare? - MedPage Today

Rheuminations: Infection or RA Flare? - MedPage Today | Immunology and Biotherapies | Scoop.it
Rheuminations: Infection or RA Flare? MedPage Today "Transplant immunology is complex, and as our arsenal of highly specific immunosuppressant and immunomodulating medications integrated into clinical practice increases, the occurrence of unusual...
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies | Immunology and Biotherapies | Scoop.it

Abstract

 

In recent years, immune checkpoints that maintain physiologic self-tolerance have been implicated in the down-regulation of anti-tumor immunity. Efforts to restore latent anti-tumor immunity have focused on antibody-based interventions targeting CTL antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells. Ipilimumab, an antibody targeting CTLA-4, appears to restore tumor immunity at the priming phase, whereas anti-PD-1/PD-L1 antibodies restore immune function in the tumor microenvironment. Although ipilimumab can produce durable long-term responses in patients with advanced melanoma, it is associated with significant immune-related toxicities. By contrast, antibodies targeting either PD-1 or PD-L1 have produced significant anti-tumor activity with considerably less toxicity. Activity was seen in patients with melanoma and renal cancer, as well as those with non-small-cell lung, bladder and head and neck cancers, tumors not previously felt to be sensitive to immunotherapy. The tolerability of PD-1-pathway blockers and their unique mechanism of action have made them ideal backbones for combination regimen development. Combination approaches involving cytotoxic chemotherapy, anti-angiogenic agents, alternative immune-checkpoint inhibitors, immunostimulatory cytokines and cancer vaccines are currently under clinical investigation. Current efforts focus on registration trials of single agents and combinations in various diseases and disease settings and identifying predictive biomarkers of response.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 3, 12:18 PM
George K. Philips and Michael AtkinsTherapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

Int. Immunol. (2015) 27 (1): 39-46 doi:10.1093/intimm/dxu095

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Gilead reports positive results from preclinical study of investigational TLR7 ... - pharmabiz.com

Gilead reports positive results from preclinical study of investigational TLR7 ... - pharmabiz.com | Immunology and Biotherapies | Scoop.it
Gilead reports positive results from preclinical study of investigational TLR7 agonist in SIV-infected, virally suppressed monkeys
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Immunogenicity of biotherapy used in psoriasis: the science behind ... - PubMed - NCBI

J Invest Dermatol. 2015 Jan;135(1):31-8. doi: 10.1038/jid.2014.295. Epub 2014 Aug 14. Review
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

T-Cell Product Candidates – Atara Biotherapeutics

T-Cell Product Candidates – Atara Biotherapeutics | Immunology and Biotherapies | Scoop.it

Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Atara's optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD), a type of malignancy occurring after allogeneic hematopoietic cell transplantation (HCT). Allogeneic HCT is also commonly called a bone marrow transplant. - 

 

The T-cell collaboration with MSK consists of three types of CTLs, each focusing on targets involved in cancers and serious infections. Using these cells, the power of the immune system can be employed to attack cancer cells and cells infected with certain viruses. T-cells may be effective even after failure of multiple other agents, and may avoid the toxicities of current treatments in patients with cancers and serious viral infections. CMV-CTLs and EBV-CTLs are currently in Phase 2 clinical trials and WT1-CTLs are currently in Phase 1 clinical studies.

 

The EBV-, CMV- and WT1-targeted T-cell product candidates share a common technology in which third-party donor-derived white blood cells are collected via leukapheresis (white blood cell collection) and are then enriched for T-cells. The T-cells are exposed to certain antigens (proteins that are recognized and attacked by the immune system), and the resulting activated T-cells are characterized and stored for future therapeutic use in a partially human leukocyte antigen, or HLA, matched patient. MSK has developed banks of these off-the-shelf, target-specific T-cell product candidates suitable for investigational use in patients with a wide range of HLA types.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 2, 9:47 AM

The Epstein-Barr virus (EBV) is a ubiquitous virus that causes infectious mononucleosis in people with normal immune function; however, in immunocompromised patients such as those undergoing hematopoietic cell or solid organ transplants, it can cause lymphoma and other cancers. EBV-CTLs are a potential third-party, donor-derived, off-the-shelf T-cell product candidate designed to target and destroy EBV-infected lymphoma cells.

 

EBV-CTLs are being studied in an ongoing Phase 2 clinical trial to test anti-tumor efficacy and safety in patients with EBV-associated lymphoproliferative disease (EBV-LPD) following allogeneic hematopoietic cell transplant (alloHCT). AlloHCT is a transplant of bone marrow stem cells from one person to another as a means to treat a variety of serious diseases, primarily blood cancers.

 

In immunocompromised people, EBV can cause lymphomas and other lymphoproliferative disorders, collectively called EBV-LPD. EBV-LPDs are a significant cause of morbidity and mortality following alloHCT. EBV-LPDs may occur in up to 6% of patients following alloHCT. There are limited treatment options, especially in those patients who have failed initial therapy with rituximab. For example, median survival from EBV-LPD diagnosis following relapse from or failure of rituximab therapy was reported by Fox and colleagues in 2014 to be 33 days among 14 patients reported and 16 days among 40 patients reported by Uhlin and coworkers in 2013.

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Newly-Found T Memory Stem Cells May Be Key to Gene Therapy - Bioscience Technology

Newly-Found T Memory Stem Cells May Be Key to Gene Therapy - Bioscience Technology | Immunology and Biotherapies | Scoop.it
Genetically engineered T memory stem cells (Tscm) can last more than 12 years in patients’ bodies, and can continually generate appropriate T cell armies for them, says an innovative study looking at two historic clinical trials.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Behind the scenes of the world's first commercial stem-cell therapy

Behind the scenes of the world's first commercial stem-cell therapy | Immunology and Biotherapies | Scoop.it
Graziella Pellegrini explains the 25-year struggle to develop Holoclar, a treatment for blindness.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy

Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy | Immunology and Biotherapies | Scoop.it
Abstract

Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical development, which belongs to a novel class of antibody constructs termed bi-specific T cell engager antibodies. This antibody construct has dual specificity for CD19 and CD3 and can re-direct polyclonal cytotoxic T lymphocytes toward the tumor. This review focuses on the pre-clinical and clinical development of blinatumomab as a powerful new tool in the treatment of B cell malignancies.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 3, 12:11 PM
Zachary Zimmerman, Tapan Maniar, and Dirk NagorsenUnleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy

Int. Immunol. (2015) 27 (1): 31-37 doi:10.1093/intimm/dxu089


Correspondence to: Z. Zimmerman, One Amgen Center Drive, MS 38-B-A, Thousand Oaks, CA 91320, USA; E-mail: zacharyz@amgen.com


Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Grand Forks team developing therapeutic antibody for canine parvovirus infections - Grand Forks Herald

Grand Forks team developing therapeutic antibody for canine parvovirus infections - Grand Forks Herald | Immunology and Biotherapies | Scoop.it
Dr. Darin Meulebroeck and his associates at Avianax, a Grand Forks-based company, are working on a therapeutic antibody for treating parvovirus infections in dogs.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Antidrug antibodies in psoriasis: a systematic review - Hsu - 2014 - British Journal of Dermatology - Wiley Online Library

Antidrug antibodies in psoriasis: a systematic review - Hsu - 2014 - British Journal of Dermatology - Wiley Online Library | Immunology and Biotherapies | Scoop.it
RT @Tildrakizumab: Antidrug antibodies in #psoriasis: a #SystematicReview Hsu 2014 British Journal of Dermatology http://t.co/BSbF3pSOyh…
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Arming the Immune System Against Cancer

Arming the Immune System Against Cancer | Immunology and Biotherapies | Scoop.it
James P. Allison, who saw the devastating effects of cancer on his family, discovered a way to disable one of its main defenses.

It was breakthrough of the year in Science two years ago


Via Krishan Maggon
more...
Chuck's curator insight, March 3, 12:14 PM

A must read....

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors | Immunology and Biotherapies | Scoop.it
Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein's power to spur cancer cell growth.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Antibody-drug conjugates (ADCs)

Antibody-drug conjugates (ADCs) | Immunology and Biotherapies | Scoop.it
In the antibody-drug conjugation (ADC) approach, highly toxic molecules are attached to highly specific antibodies thereby increasing their tumor cell-killing capability.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Immune Modulation by Inducing Antibody

Antibody therapies for immune modulation are an exciting innovative area of discovery in immunotherapy research. As a substitute to chemotherapy immune modulation they offer a defined mechanism of action as the target is known.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

25 years of lung transplantation: "Second wind" from Vienna - HealthCanal.com

25 years of lung transplantation: "Second wind" from Vienna - HealthCanal.com | Immunology and Biotherapies | Scoop.it
25 years of lung transplantation: "Second wind" from Vienna
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine ... - Business Wire (press release)

Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine ... - Business Wire (press release) | Immunology and Biotherapies | Scoop.it
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”) announced today positive results from a Phase IIb study evaluating the efficacy,
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Human Monoclonal Antibodies (HuMabs) Program | Vaccinogen

OncoVAX uses Monoclonal antibodies which represent one of the most significant advances in cancer treatment over the past 20 years.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, February 28, 2:48 AM

OncoVax  uses mabs. 

 

OncoVAX® is an autologous cancer vaccine manufactured with a patented process to leverage a patient’s own tumor cells to launch a potent and customized immune response against residual cancer cells that may reside in the body after surgery.  Killing these residual cells is key to preventing the recurrence of the cancer.

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies - Nature.com

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies
Nature.com
After 8–10 days in culture, the cells are pooled and analyzed by flow cytometry after staining with virus-specific human leukocyte antigen tetramers.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Stem Cells Phone Home - The Scientist | News & Opinions (press release) (registration) (blog)

Stem Cells Phone Home - The Scientist | News & Opinions (press release) (registration) (blog) | Immunology and Biotherapies | Scoop.it
A screen of 9,000 small molecules identifies a treatment that improves the targeting of mesenchymal stem cells to sites of damaged tissue.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Therapeutic uses of anti-interleukin-6 receptor antibody

Therapeutic uses of anti-interleukin-6 receptor antibody | Immunology and Biotherapies | Scoop.it
Abstract

Cytokine-targeted therapy has generated a paradigm shift in the treatment of several immune-mediated diseases. Interleukin-6 (IL-6), which was initially identified as B-cell stimulatory factor 2, is a prototypical cytokine with wide-ranging biological effects on immune cells such as B and T cells, on hepatocytes, hematopoietic cells, vascular endothelial cells and on many others. IL-6 is thus crucially involved in the regulation of immune responses, hematopoiesis and inflammation. When infections and tissue injuries occur, IL-6 is promptly synthesized and performs a protective role in host defense against such stresses and traumas. However, excessive production of IL-6 during this emergent process induces potentially fatal complications, including systemic inflammatory response syndrome (SIRS), and dysregulated, persistently high expression of IL-6 causes the onset or development of various chronic immune-mediated disorders. For these reasons, IL-6 blockade was expected to become a novel therapeutic strategy for various diseases characterized by IL-6 overproduction. Indeed, worldwide clinical trials of tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody, have successfully proved its outstanding efficacy against rheumatoid arthritis, juvenile idiopathic arthritis and Castleman disease, leading to the approval of tocilizumab for the treatment of these diseases. Moreover, various reports regarding off-label use of tocilizumab strongly suggest that it will be widely applicable for acute, severe complications such as SIRS and cytokine-release syndrome and other refractory chronic immune-mediated diseases.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 3, 1:00 PM
Sujin Kang, Toshio Tanaka, and Tadamitsu KishimotoTherapeutic uses of anti-interleukin-6 receptor antibody

Int. Immunol. (2015) 27 (1): 21-29 doi:10.1093/intimm/dxu081

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Introduction: Antibody-Targeted Therapy Special Issue

Introduction: Antibody-Targeted Therapy Special Issue | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 4, 3:26 AM
Oxford JournalsMedicine & Health & Science & MathematicsInternational ImmunologyVolume 27, Issue 1Pp. 1-2.

  Introduction: Antibody-Targeted Therapy Special IssueTadamitsu Kishimoto
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen | Immunology and Biotherapies | Scoop.it
Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Stable Linker - ADC | BioOncology

Stable linkers allow ADCs to remain inactive while in circulation and prevent the release of cytotoxic agents prematurely. Learn how linkers deliver cytotoxic agents to help fight cancer.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Antibody-drug conjugate (ADC) clinical pipeline: a review. - PubMed - NCBI

Methods Mol Biol. 2013;1045:1-27. doi: 10.1007/978-1-62703-541-5_1. Review
Gilbert Faure au nom de l'ASSIM's insight:

Lessons learned from the first-generation antibody-drug conjugate (ADC) and improvement of the technology guided the design of improved compounds which are now in clinical trials. Brentuximab vedotin (Adcetris(®)), an anti-CD30 antibody conjugated to a potent microtubule inhibitor for the treatment of Hodgkin's lymphoma and anaplastic large cell lymphomas, is the only marketed ADC today. A total of 27 ADC are currently undergoing clinical trials in both hematological malignancies and solid tumor indications. Among them, T-DM1 (trastuzumab emtansine), an ADC comprised of trastuzumab conjugated to DM1, via a non-cleavable linker, is showing very promising results in phase III for the treatment of HER2-positive refractory/relapsed metastatic breast cancer. Other compounds, such as CMC-544, SAR3419, CDX-011, PSMA-ADC, BT-062, and IMGN901 currently in clinical trials, targeting varied antigens and bearing different linker and drugs, contribute to the learning curve of ADC, as do the discontinued ADC. Current challenges include improvement of the therapeutic index, linked to a careful selection of the targets, a better understanding of ADC mechanism of action, the management and understanding of ADC off-target toxicities, as well as the selection of appropriate clinical settings (patient selection, dosing regimen) where these molecules can bring highest clinical be

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Ibalizumab (TaiMed Biologics, WuXi PharmTech) gets FDA Breakthrough Therapy designation for HIV

Ibalizumab (TaiMed Biologics, WuXi PharmTech) gets FDA Breakthrough Therapy designation for HIV | Immunology and Biotherapies | Scoop.it

TMB-355(Ibalizumab) is a humanized monoclonal antibody (mAb) and a member of an emerging class of HIV therapies known as viral-entry inhibitors. This drug candidate is distinct from other entry inhibitors in that it binds to the CD4 molecule, the primary receptor for HIV infection, thereby interfering with the penetration of the virus into the cell. It is the first entry-blocking humanized mAb to treat HIV/AIDS. TMB-355 caught the attention of the scientific community in February 2003, when results from the phase-1, single-dose clinical trial showed a transient but clinically significant reduction in the patients’ viral load. Moreover, it was well tolerated with no evidence of adverse effects on CD4 T-cells of treated subjects unlike the majority of approved drugs for HIV. The U.S. FDA granted TMB-355 fast track status in October 2003. The phase-2a clinical trial was successfully completed in 2006, with the results showing a clean safety profile and clear antiviral activity (10-fold reduction in viral load).  The Phase-2b clinical trial was also successfully completed in 2011. TaiMed Biologics is concurrently developing a subcutaneous injection dosage form and a phase 1 human pharmacokinetics bridging study is completed in 2012. Currently, TMB is developing a phase I/II study for HIV-negative and new HIV-positive subjects to begin by the end of 2012.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 2, 8:03 AM

This is a first for a Chinese company to get FDA breakthrough therapy designation.  It was discovered by Tanox now part of Genentech/Roche and licensed to TaiMed Biologics. WuXi has licensed the marketing rights.